Ionis Pharmaceuticals (NASDAQ:IONS) Lifted to "Hold" at Stoc

StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a report published on Tuesday. IONS has been the subject of a number of other reports. The Goldman Sachs Group increased their price target on Ionis Pharmaceuticals from $25.00 to $28.00 and gave the company a […]

Related Keywords

Canada , United States , William Blair , Raymond James , Almanack Investment Partners , Institutional Trading Of Ionis Pharmaceuticals , Peoples Bank , Ionis Pharmaceuticals , Goldman Sachs Group , Ionis Pharmaceuticals Company Profile , Analyst Recommendations For Ionis Pharmaceuticals , Royal Bank , Securities Exchange Commission , Morgan Stanley , Ionis Pharmaceuticals Stock Performance , Horizon Investments , Ionis Pharmaceuticals Inc , News Ratings For Ionis Pharmaceuticals Daily , Free Report , Get Free Report , Director Joseph Klein , Exchange Commission , Investment Partners , Financial Advisors , Ionis Pharmaceuticals Daily , Nasdaq Ions , Lions , Medical , 46433010 , Upgrade , Stocknews Com ,